PDEX vs PFE

Pro-Dex Inc. remains a financially robust and profitable specialized contract manufacturer, characterized by a strong balance sheet and stable profitability (TTM revenue $66.59M, net income $8.98M, TTM P/E ~20.16 based on current price and EPS). Fiscal 2025 revenue grew 23.68% YoY. However, its fundamental business model, while essential and reliable, does not exhibit the disruptive innovation, ex...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...